Pfizer, in collaboration with Bain Capital, announced the creation of Cerevel Therapeutics, a new biopharmaceutical company focused on developing drug candidates to treat disorders of the central nervous system.
Medical technology company Axonics Modulation Technologies is offering more than 6 million shares in an initial public offering valued up to more than $122 million.
Here are five biotech stocks that are rated Buy by the Jefferies analysts, are trading under the $10 level and could provide investors with some solid upside potential.
Clovis Oncology shares dropped on Friday after the company announced initial data from its Phase 2 clinical trial of Rubraca at the ESMO 2018 Congress.
Merrimack Pharmaceuticals shares dropped early on Friday after the company announced that it would be terminating its midstage SHERLOC study in patients with non-small cell lung cancer.
Genome editing company LogicBio Therapeutics expects to price more than 5 million shares for an initial public offering valued up to almost $93 million.
Proteostasis Therapeutics shares absolutely exploded on Thursday after the company announced positive preliminary results from its early-stage cystic fibrosis trial.